One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: Evidence from a parallel group randomized trial

International Journal of Geriatric Psychiatry

Volumn 27, Issue 1, 2012, Pages 49-58

  Tendolkar, Indira ^a   Enajat, Morteza ^b   Zwiers, Marcel P ^a   Van Wingen, Guido ^a   De Leeuw, Frank Erik ^b   Van Kuilenburg, Janet ^b   Bouwels, Leon ^c   Pop, Gheorghe ^b   Pop Purceleanu, Monika ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

amygdala; cholesterol lowering treatment; hippocampus; memory

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADD ON THERAPY; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYGDALOID NUCLEUS; ANTICOAGULANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN ATROPHY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM MEMORY; MALE; MEMORY DISORDER; MYALGIA; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL; SHORT TERM MEMORY; SIDE EFFECT; TEMPORAL LOBE; WHITE MATTER;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATROPHY; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MEMORY; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; PYRROLES; TEMPORAL LOBE;

EID: 82955184474     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2688     Document Type: Article

References (53)

1. Amarenco P, Goldstein LB, Szarek M, et al,., SPARCL Investigators. 2007. Effects of intense low density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38: 3198-31204.
2. Artero S, Tiemeier H, Prins ND, et al,. 2004. Neuroanatomical localisation and clinical correlates of white matter lesions in the elderly. J Neurol Neurosurg Psychiatry 75: 1304-1308. (Pubitemid 39141339)
3. Ashburner J, Friston K,. 1997. Multimodal image coregistration and partitioning-a unified framework. Neuroimage 6: 209-217. (Pubitemid 27488452)
4. Barber R, Ballard C, McKeith IG,. 2000. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 54: 1304-1309. (Pubitemid 30174051)
5. Basso M, Yang J, Warren L, et al,. 2006. Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease. Psychiatry Res 146: 251-261. (Pubitemid 43782725)
6. Braak H, Braak E,. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
7. Breteler MM,. 2000. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 903: 457-465. (Pubitemid 30251589)
8. Bunch TJ, Weiss JP, Crandall BG, et al,. 2010. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 7: 433-437.
9. Clarke RM, O'Connell F, Lyons A, Lynch MA,. 2007. The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta 1-42 in the rat hippocampus in vivo. Neuropharmacology 52: 136-145. (Pubitemid 46026837)
10. Corradi D, Callegari S, Maestri R, Benussi S, Alfieri O,. 2008. Structural remodeling in atrial fibrillation. Nat Clin Pract Cardiovasc Med 5: 782-796.
11. de Groot JC, de Leeuw FE, Oudkerk M,. 2000. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 47: 145-151. (Pubitemid 30078560)
12. de la Torre JC,. 2006. How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res 28: 637-644. (Pubitemid 44433323)
13. Den Heijer T, Launer LJ, Prins ND, et al,. 2005. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 64: 263-267.
14. Di Napoli P, Taccardi AA, Oliver M, De Caterina R,. 2002. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 23: 1908-1921. (Pubitemid 35448549)
15. Duvernoy H,. 1997. The Human Hippocampus, Functional Anatomy, Vascularization and Serial Sections With MRI (Hardcover). Springer-Verlag: New York.
16. Eichenbaum H, Yonelinas AP, Ranganath C,. 2007. The medial temporal lobe and recognition memory. Annu Rev Neurosci 30: 123-152. (Pubitemid 47224758)
17. Enajat M, Teerenstra S, van Kuilenburg JT, et al,. 2009. Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: a randomized, double-blind, placebo-controlled study. Drugs Aging 26: 585-593.
18. Folstein MF, Folstein SE, McHugh PR,. 1975. " Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
19. Geuze E, Vermetten E, Bremner JD,. 2005. MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Mol Psychiatry 10: 160-184. (Pubitemid 40188512)
20. Hege SG, Ellinwood EH Jr, Wilson WH, Helligers CA, Graham SM,. 1997. Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam. Psychopharmacology 131: 101-107. (Pubitemid 27261596)
21. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA,. 2000. Statins and the risk of dementia. Lancet 356: 1627-1631.
22. Kastelijn JJP, Akdim F, Stroes ESG, et al,., ENHANCE Investigators. 2008. Simvastatin with or without ezetimibe in familial hypercholsterolemia. N Engl J Med 358: 1431-1443. (Pubitemid 351482735)
23. Kilander L, Andrén B, Nyman H, et al,. 1998. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 29: 1816-1820. (Pubitemid 28399970)
24. Knecht S, Oelschläger C, Duning T, et al,. 2008. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J [Epub ahead].
25. Korf ES, van Straaten EC, de Leeuw FE, et al,., LADIS Study Group. 2007. Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabetes Med 24: 166-171. (Pubitemid 46174940)
26. Koudinov AR, Koudinova NV,. 2001. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15: 1858-1860.
27. Krasuski JS, Alexander GE, Horwitz B,. 1998. Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biol Psychiatry 43: 60-68. (Pubitemid 28059073)
28. Lawton MP, Brody EM,. 1969. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186.
29. Lioudaki E, Ganotakis ES, Mikhailidis DP,. 2011. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 9: 62-86.
30. Loricchio ML, Cianfrocca C, Pasceri V, et al,. 2007. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 99: 1421-1424. (Pubitemid 46691310)
31. Lynch AM, Loane DJ, Minogue AM, et al,. 2007. Eicosapentaenoic acid confers neuroprotection in the amyloid-beta challenged aged hippocampus. Neurobiol Aging 6: 845-855. (Pubitemid 46589740)
32. Mead GE, Keir S,. 2001. Association between cognitive impairment and atrial fibrillation: a systematic review. J Stroke Cerebrovasc Dis 10: 35-43. (Pubitemid 32489092)
33. Miyasaka Y, Barnes ME, Petersen RC, et al,. 2007. Risk of dementia instroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 28: 1962-1967. (Pubitemid 47579533)
34. O'Brien JT, Desmond P, Ames D, et al,. 1997. Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment. Psychol Med 27: 1267-1275. (Pubitemid 27494092)
35. Proust-Limal C, Amieva H, Dartigues JF, Jacqmin-Gadda1 H,. 2007. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol 165: 344-350. (Pubitemid 46174759)
36. Ridker PM, Danielson E, Fonseca FA, et al,., JUPITER Study Group. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
37. Rutishauser U, Mamelak AN, Schuman EM,. 2006. Single-trial learning of novel stimuli by individual neurons of the human hippocampus-amygdala complex. Neuron 49: 805-813. (Pubitemid 43376078)
38. Saan RJ, Deelman BG,. 1986. De 15-Woorden Tests A en B (Een voorlopige handleiding). Afdeling Neuropsychologie: Groningen.
39. Sachdev PS, Chen X, Joscelyne A, Wen W, Brodaty H,. 2007. Amygdala in stroke/transient ischemic attack patients and its relationship to cognitive impairment and psychopathology: the Sydney Stroke Study. Am J Geriatr Psychiatry 15: 487-496.
40. Sager PT, Capece R, Lipka L,. 2005. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179: 361-367. (Pubitemid 40364632)
41. Scanlon SM, Williams DC, Schloss P,. 2001. Membrane cholesterol modulates serotonin transporter activity. Biochemistry 40: 10507-10513. (Pubitemid 32816661)
42. Scott AS, DeKosky ST, Scheff SW,. 1991. Volumetric atrophy of the amygdala in Alzheimer's disease: quantitative serial reconstruction. Neurology 41: 351-356.
43. Sparks DL, Sabbagh MN, Connor DJ, et al,. 2005. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62: 753-757. (Pubitemid 40656090)
44. Stepien K, Tomaszewksi M, Czucwar SJ,. 2005. Neuroprotective properties of statins. Pharm Rep 57: 561-569.
45. Vakil E, Blachstein H,., 1993. Rey Auditory-Verbal Learning Test: Structure analysis. J Clin Psychol 49: 883-890. (Pubitemid 23361803)
46. Van Breukelen GJP,. 2006. ANCOVA versus change from baseline had more power in randomized studies and more bias in nonrandomized studies. J Clin Epidemiol 59: 920-925. (Pubitemid 44163423)
47. van de Pol LA, Korf ES, van der Flier WM, et al,. 2007. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol 64: 1023-1028. (Pubitemid 47048004)
48. van Eijndhoven P, van Wingen G, van Ooijen K, et al,. 2009. Amygdala volume marks the acute state in the early course of depression. Biol Psychiatry 65: 812-818.
49. van Norden AG, Fick WF, de Laat KF, et al,. 2008. Subjective cognitive failures and hippocampal volume in elderly with white matter. Neurology 71: 1152-1159.
50. Verma S, Szmitko PE, Ridker PM,. 2005. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2: 29-36. (Pubitemid 40823207)
51. Wechsler, D,. 1955. Wechsler Adult Intelligence Scale. Manual. Psychological Corp.: New York.
52. Wechsler, D,. 2000. WAIS-III Nederlandstalige Bewerking. Technische Handleiding. Swets & Zeitlinger: Lisse.
53. Wezenberg E, Sabbe BGC, Hulstijn W, Ruigt GSF, Verkes RJ,. 2007. The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions. J Psychopharmacol 21: 579-587. (Pubitemid 47472724)